Lobe Sciences Ltd.
Lobe Sciences Ltd.
The Company is working to develop psychedelic compounds as therapeutics. Initially the Company will develop psilocybin-based therapeutics in combination with N-acetylcysteine for the treatment of mild traumatic brain injuries and post-traumatic stress disorder and devices for the efficient application of these medications. The Company also owned acquired brands, intellectual property and leases office and production premises to a cannabis processor and retailer which were disposed of on March 5, 2021.
Lobe Sciences Ltd. (LOBE)
SEDAR Information
Company Info
Capitalization
Company Officers
News Releases
News release
News release
Bulletins
2022-0613 – Consolidation - Lobe Sciences Ltd. (LOBE)
le 9 juin/June 2022
Lobe Sciences Ltd. (the "Issuer") has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every six (6) pre-consolidated common shares.
As a result, the outstanding common shares of the Issuer will be reduced to approximately 38,230,000 common shares.
